Greenwich LifeSciences reported a 33% rise in the annual patient screening rate for its Phase III FLAMINGO‑01 trial, bringing the rate to more than 800 patients per year from the previously reported 600. The increase reflects new site activations in 2025 and stronger enrollment momentum at existing sites.
The company also confirmed that the 250‑patient non‑HLA‑A*02 arm is now fully enrolled and that more than 1,000 patients have been screened to date, underscoring the trial’s rapid expansion.
Preliminary analysis of the non‑HLA‑A*02 cohort shows an approximately 80% reduction in recurrence rates after the primary immunization series, a promising signal that aligns with earlier Phase IIb results and could accelerate the trial’s primary endpoint timeline.
CEO Snehal Patel noted, “While the approximately 33% increase to over 800 patients screened per year is impressive, marking our success in optimizing and expanding our clinical operations in 2025, we may have yet to see the peak screen rate for the study.” The comment highlights the company’s confidence in sustaining enrollment momentum.
The accelerated screening pace is expected to shorten the time required to accumulate the data needed for the primary endpoint, potentially reducing the overall trial duration and associated costs. The progress also bolsters investor confidence in GLSI’s ability to meet its clinical milestones, which may ease future financing pressures for the clinical‑stage company.
Analysts have expressed increased optimism about GLSI’s prospects, citing the encouraging efficacy data and the trial’s rapid enrollment as key factors driving a more favorable outlook.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.